The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of a PD-L1 antibody (Durvalumab) in combination with trastuzumab in HER-2 positive metastatic breast cancer (MBC) progressing on prior anti HER-2 therapies (CCTG IND.229)[NCT02649686].
 
Stephen K. L. Chia
Honoraria - Genomic Health; Novartis
Consulting or Advisory Role - Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Genentech (Inst); Genomic Health (Inst); Novartis (Inst); Roche (Inst)
 
Philippe L. Bedard
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Cascadian Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); PTC Therapeutics (Inst); Sanofi (Inst); SERVIER (Inst); SignalChem (Inst)
 
John Hilton
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly
 
Eitan Amir
No Relationships to Disclose
 
Karen A. Gelmon
Consulting or Advisory Role - AstraZeneca; Merck; NanoString Technologies; Novartis; Pfizer
 
Rachel Anne Goodwin
Honoraria - Ipsen; Novartis
Consulting or Advisory Role - Ipsen; Lilly; Novartis
Research Funding - Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Diego Villa
Honoraria - Abbvie; Celgene; Gilead Sciences; Janssen; Lundbeck; Roche
Consulting or Advisory Role - Celgene; Gilead Sciences; Janssen; Lundbeck; Roche
Research Funding - Roche (Inst)
 
Michael Cabanero
No Relationships to Disclose
 
Heather Ritter
No Relationships to Disclose
 
Dongsheng Tu
No Relationships to Disclose
 
Ming Sound Tsao
Honoraria - Bristol-Myers Squibb; Merck; Ventana Medical Systems
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Prognostic gene signature for early stage non-small cell lung cancer
 
Lesley Seymour
Stock and Other Ownership Interests - AstraZeneca
Consulting or Advisory Role - Boehringer Ingelheim; Hanmi; Shire (Inst)
Research Funding - AstraZeneca (Inst); Innate Pharma (Inst); Merck (Inst); Oncolytics (Inst); Pfizer (Inst); Senhwa Biosciences (Inst)